Conbercept is currently in clinical development for treatment of adults (aged 50 years older) with Neovascular age-related macular degeneration (AMD), also known as wet AMD, a chronic eye disease. This disease is characterised by the formation of immature blood vessels that grow between the retina (macula; a layer of tissue in the back of the eye that senses light and sends images to the brain). Such blood vessels easily haemorrhage and cause scarring, which leads to vision impairment and is a leading cause of central sight loss and blindness. Conbercept is a novel protein that is administered via injection into the eye (intravitreal injection). Its main function is to inhibit the vascular endothelial growth factor (VEGF), a protein that promotes he growth of new blood vessels. As conbercept blocks VEGF it leads to reduced growth of the abnormal blood vessels to treat neovascular AMD. If licensed, Conbercept may offer an additional treatment option for patients with neovascular AMD.